文献速递免疫规划妇幼与学校卫生传染病防控与疫情报告

妊娠期接种COVID-19疫苗与早产或小于胎龄儿——美国八家综合卫生保健组织,2020年12月15日至2021年7月22日

Receipt of COVID-19 Vaccine During Pregnancy and Preterm or Small-for-Gestational-Age at Birth - Eight Integrated Health Care Organizations, United States, December 15, 2020-July 22, 2021.
PubMed 文献 · MMWR Morb Mortal Wkly Rep · 2022-01-07

这项回顾性队列研究基于美国八家疫苗安全数据链(VSD)卫生保健组织的活产数据,评估妊娠期接种COVID-19疫苗与早产及小于胎龄儿(SGA)的风险。在46,079名有活产且孕周可用的孕妇中,10,064名(21.8%)在妊娠期接种至少一剂COVID-19疫苗。妊娠期接种与早产(aHR=0.91;95%CI=0.82-1.01)及SGA(aHR=0.95;95%CI=0.87-1.03)均无显著关联。

要点

  • 妊娠期接种COVID-19疫苗与早产风险无显著关联(aHR=0.91;95%CI=0.82-1.01)。
  • 妊娠期接种COVID-19疫苗与小于胎龄儿风险无显著关联(aHR=0.95;95%CI=0.87-1.03)。
  • 因早孕期暴露数量少,无法计算早孕期接种的aHR。

核心结论

  • 妊娠期接种COVID-19疫苗与早产或小于胎龄儿风险无显著关联,这些数据为妊娠期接种COVID-19疫苗的安全性提供了支持证据。

研究设计与样本

  • 回顾性队列研究,纳入美国八家疫苗安全数据链(VSD)卫生保健组织中2020年5月17日至10月24日估计末次月经开始或结束的单胎妊娠活产。
  • 共46,079名有活产且孕周可用的孕妇纳入分析,其中10,064名(21.8%)在2020年12月15日至2021年7月22日期间妊娠期接种至少一剂COVID-19疫苗。
  • 在接种疫苗的孕妇中,9,892名(98.3%)在第二或第三孕期接种。
  • 分析中考虑了时间依赖的疫苗暴露和接种倾向。

主要发现

  • 妊娠期接种COVID-19疫苗与早产(<37孕周)风险无显著关联(aHR=0.91;95%CI=0.82-1.01)。
  • 在40,627名有出生体重数据的活产中,妊娠期接种COVID-19疫苗与小于胎龄儿(出生体重<同孕周第10百分位)风险无显著关联(aHR=0.95;95%CI=0.87-1.03)。
  • 按mRNA COVID-19疫苗剂量或第二、第三孕期接种分层分析,与未接种孕妇相比,结果一致显示风险未增加。
  • 因早孕期暴露数量少,无法计算早孕期接种的aHR。

临床怎么用

  • CDC建议孕妇、近期孕妇(包括哺乳期妇女)、正在尝试怀孕或未来可能怀孕的女性接种COVID-19疫苗,以降低COVID-19相关重症风险。

局限性

  • 因早孕期暴露数量少,无法计算早孕期接种的aHR。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

COVID-19 vaccines are recommended during pregnancy to prevent severe maternal morbidity and adverse birth outcomes; however, vaccination coverage among pregnant women has been low (1). Concerns among pregnant women regarding vaccine safety are a persistent barrier to vaccine acceptance during pregnancy. Previous studies of maternal COVID-19 vaccination and birth outcomes have been limited by small sample size (2) or lack of an unvaccinated comparison group (3). In this retrospective cohort study of live births from eight Vaccine Safety Datalink (VSD) health care organizations, risks for preterm birth (<37 weeks' gestation) and small-for-gestational-age (SGA) at birth (birthweight <10th percentile for gestational age) after COVID-19 vaccination (receipt of ≥1 COVID-19 vaccine doses) during pregnancy were evaluated. Risks for preterm and SGA at birth among vaccinated and unvaccinated pregnant women were compared, accounting for time-dependent vaccine exposures and propensity to be vaccinated. Single-gestation pregnancies with estimated start or last menstrual period during May 17-October 24, 2020, were eligible for inclusion. Among 46,079 pregnant women with live births and gestational age available, 10,064 (21.8%) received ≥1 COVID-19 vaccine doses during pregnancy and during December 15, 2020-July 22, 2021; nearly all (9,892; 98.3%) were vaccinated during the second or third trimester. COVID-19 vaccination during pregnancy was not associated with preterm birth (adjusted hazard ratio [aHR] = 0.91; 95% CI = 0.82-1.01). Among 40,627 live births with birthweight available, COVID-19 vaccination in pregnancy was not associated with SGA at birth (aHR = 0.95; 95% CI = 0.87-1.03). Results consistently showed no increased risk when stratified by mRNA COVID-19 vaccine dose, or by second or third trimester vaccination, compared with risk among unvaccinated pregnant women. Because of the small number of first-trimester exposures, aHRs for first-trimester vaccination could not be calculated. These data add to the evidence supporting the safety of COVID-19 vaccination during pregnancy. To reduce the risk for severe COVID-19-associated illness, CDC recommends COVID-19 vaccination for women who are pregnant, recently pregnant (including those who are lactating), who are trying to become pregnant now, or who might become pregnant in the future (4).

来源:MMWR Morb Mortal Wkly Rep,查看原文。版权归原作者所有。

引用

  1. Lipkind HS, Vazquez-Benitez G, DeSilva M, et al. Receipt of COVID-19 Vaccine During Pregnancy and Preterm or Small-for-Gestational-Age at Birth - Eight Integrated Health Care Organizations, United States, December 15, 2020-July 22, 2021. MMWR Morb Mortal Wkly Rep. 2022. PMID: 34990445. doi:10.15585/mmwr.mm7101e1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。